We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Alnylam's Givosiran Gets Breakthrough Therapy Status by FDA
Read MoreHide Full Article
Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) announced that it has received Breakthrough Therapy designation from the FDA for pipeline candidate givosiran (ALN-AS1), for the prophylaxis of attacks in patients with acute hepatic porphyria (AHP).
We note that Givosiran is being evaluated for the treatment of acute hepatic porphyrias, including acute intermittent porphyria (AIP).
A look at Alnylam’s year-to-date share price movement shows that the stock has outperformed the Zacks classified Medical-Biomed/Genetics industry. Share price has increased 74.8% year to date against the industry’s decline of 0.5%.
The Breakthrough Therapy designation was based on the encouraging results from the ongoing phase I study of givosiran. Findings demonstrated robust and durable reduction in the occurrence of porphyria attacks. Updated results from this trial will be provided in an oral presentation on Jun 26, 2017 at the International Congress on Porphyrins and Porphyrias (ICPP).
Breakthrough Therapy Designation from the FDA will expedite the development and review of drugs that are intended to treat serious diseases and should provide access of the drug to patients as soon as possible.
Givosiran has also been granted Orphan Drug Designations in both the E.U. and the U.S. for the treatment of acute hepatic porphyrias. In Mar 2017, the European Medicines Agency (EMA) granted givosiran PRIME Designation for accelerated assessment for the treatment of porphyria based on positive data from the phase I study. The company plans to initiate the phase III study with givosiran in late 2017.
A potential approval will significantly boost the growth prospects of the company.
Alnylam carries a Zacks Rank#3 (Hold). Some better ranked stocks in the health care sector include VIVUS, Inc. , MEI Pharma, Inc. (MEIP - Free Report) and Aeglea BioTherapeutics . While VIVUS and MEI Pharma sport a Zacks Rank #1 (Strong Buy), Aeglea carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
VIVUS’ loss per share estimates narrowed from 50 cents to 39 cents for 2017 over the last 30 days. The company posted positive earnings surprises in all of the four trailing quarters, with an average beat of 233.69%.
MEI Pharma’s estimates narrowed from loss per share of 1 cent to gain per share of 1 cent for 2017 over the last 30 days. The company posted positive earnings surprises in three of the four trailing quarters, with an average beat of 66.56%.
Aeglea’s loss per share estimates narrowed from $3.64 to $2.48 for 2017 over the last 60 days. The company posted positive earnings surprises in three of the four trailing quarters, with an average beat of 20.75%.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge. With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research. It's not the one you think. See This Ticker Free >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Alnylam's Givosiran Gets Breakthrough Therapy Status by FDA
Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) announced that it has received Breakthrough Therapy designation from the FDA for pipeline candidate givosiran (ALN-AS1), for the prophylaxis of attacks in patients with acute hepatic porphyria (AHP).
We note that Givosiran is being evaluated for the treatment of acute hepatic porphyrias, including acute intermittent porphyria (AIP).
A look at Alnylam’s year-to-date share price movement shows that the stock has outperformed the Zacks classified Medical-Biomed/Genetics industry. Share price has increased 74.8% year to date against the industry’s decline of 0.5%.
The Breakthrough Therapy designation was based on the encouraging results from the ongoing phase I study of givosiran. Findings demonstrated robust and durable reduction in the occurrence of porphyria attacks. Updated results from this trial will be provided in an oral presentation on Jun 26, 2017 at the International Congress on Porphyrins and Porphyrias (ICPP).
Breakthrough Therapy Designation from the FDA will expedite the development and review of drugs that are intended to treat serious diseases and should provide access of the drug to patients as soon as possible.
Givosiran has also been granted Orphan Drug Designations in both the E.U. and the U.S. for the treatment of acute hepatic porphyrias. In Mar 2017, the European Medicines Agency (EMA) granted givosiran PRIME Designation for accelerated assessment for the treatment of porphyria based on positive data from the phase I study. The company plans to initiate the phase III study with givosiran in late 2017.
A potential approval will significantly boost the growth prospects of the company.
Alnylam Pharmaceuticals, Inc. Price
Alnylam Pharmaceuticals, Inc. Price | Alnylam Pharmaceuticals, Inc. Quote
Zacks Rank and Stocks to Consider
Alnylam carries a Zacks Rank#3 (Hold). Some better ranked stocks in the health care sector include VIVUS, Inc. , MEI Pharma, Inc. (MEIP - Free Report) and Aeglea BioTherapeutics . While VIVUS and MEI Pharma sport a Zacks Rank #1 (Strong Buy), Aeglea carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
VIVUS’ loss per share estimates narrowed from 50 cents to 39 cents for 2017 over the last 30 days. The company posted positive earnings surprises in all of the four trailing quarters, with an average beat of 233.69%.
MEI Pharma’s estimates narrowed from loss per share of 1 cent to gain per share of 1 cent for 2017 over the last 30 days. The company posted positive earnings surprises in three of the four trailing quarters, with an average beat of 66.56%.
Aeglea’s loss per share estimates narrowed from $3.64 to $2.48 for 2017 over the last 60 days. The company posted positive earnings surprises in three of the four trailing quarters, with an average beat of 20.75%.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge. With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research. It's not the one you think. See This Ticker Free >>